Sally Arai
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Division: Blood and Marrow Transplantation
- Member, Cancer Center
Contact Information
-
Clinical Offices
Blood and Marrow Transplant Program 300 Pasteur Dr H3249 MC 5623 Stanford, CA 94305 Tel Work (650) 723-0822 Fax (650) 725-8950
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Snapshot
Clinical Focus
- Bone Marrow Transplant
- Hematology
- Blood and Marrow Transplantation
Honors and Awards
- K23-“Reduce GVHD and Relapse using Ex-Vivo Expanded Allogeneic Cell Therapy”, NIH (2003-2008)
- “A phase I/II study of post-transplant autologous CIK cells for high-risk hematologic malignancies”, Cancer Treatment Research Foundation (2005-2009)
Professional Education
| Board Certification: | Hematology, American Board of Internal Medicine (2001) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (1999) |
| Fellowship: | John Hopkins Hospital, MD (1999) |
| Fellowship: | Mount Sinai Medical Center, NY (1998) |
| Residency: | Strong Memorial Hospital, NY (1995) |
Graduate & Fellowship Program Affiliations
Scientific Focus
Current Research Interests
Research interest in utilizing post-transplant adoptive cellular immunotherapy to reduce GVHD and relapse in patients with high risk hematologic malignancies.
Clinical Trials
- A Phase II Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft versus Host Disease Recruiting
- Chronic GVHD Cohort Protocol Recruiting
- Defibrotide for Hematopoietic SCT Patients With Severe Hepatic VOD: a Treatment IND Study Recruiting
- Allogeneic HCT using Nonmyeloablative Host Conditioning with TLI & ATG vs SOC in AML Recruiting
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Recruiting
Publications
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008; (6): 625-32
- A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007; (6): 634-41
- Natural killer cells: can they be useful as adoptive immunotherapy for cancer? Expert Opin Biol Ther. 2005: 163-172
- Association of Foxp3 regulatory gene expression and graft-versus-host disease Blood. 2004: 2187-93
- Poor outcome in steroid refractory GVHD with ATG treatment Biol Blood Marrow Transplant. 2002: 155-60
Help
Trial Administration